Ibudilast – (50847-11-5)

Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug primarily used in Japan. It acts as a phosphodiesterase inhibitor, predominantly inhibiting the PDE4 subtype, but also showing significant inhibition of other PDE subtypes.

Ibudilast has bronchodilator, vasodilator, and neuroprotective effects, and may be useful in reducing addiction to methamphetamine, opioids, and alcohol. It crosses the blood-brain barrier, suppresses glial cell activation, and has potential applications in treating neuropathic pain and multiple sclerosis.

Ibudilast also inhibits platelet aggregation and has shown promise in enhancing analgesia produced by opioid drugs while reducing tolerance development. Its pharmacodynamics involve PDE4 inhibition and antagonism at the toll-like receptor 4 (TLR4), contributing to its anti-inflammatory and pain-relieving effects.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Ibudilast
https://www.medchemexpress.com/Ibudilast.html
https://www.medkoo.com/products/7771
https://go.drugbank.com/drugs/DB05266
https://pubchem.ncbi.nlm.nih.gov/compound/Ibudilast